Abstract
Background: The existence of tumor‐initiating cells (TICs) has been described in head and neck cancers. Plasminogen activator inhibitor‐1 (PAI‐1) has been demonstrated to act as a prognostic factor in head and neck cancers.Methods: Tiplaxtinin (PAI‐039), a specific inhibitor of PAI‐1, and PAI‐1‐specific siRNA were used to examine the role of PAI‐1 in the self‐renewal property of head and neck cancer‐TICs by tumorsphere formation. Western blot, real‐time polymerase chain reaction, and luciferase‐based reporter assay were used to study the effect of PAI‐039 in the sex‐determining region Y‐box 2 (Sox2) expression.Results: PAI‐039 suppressed the self‐renewal capability of head and neck cancer‐TICs derived from head and neck cancer cell lines through the inhibition of Sox2 expression. PAI‐039 decreased the activity of the core promoter and the enhancer of the Sox2 gene in head and neck cancer‐TICs. Knockdown of PAI‐1 expression also inhibited self‐renewal and radioresistance properties of head and neck cancer‐TICs.Conclusion: The inhibition of PAI‐1 by PAI‐039 or siRNA could suppress head and neck cancer‐TICs within head and neck cancer cell lines through the downregulation of Sox2. © 2015 Wiley Periodicals, Inc. Head Neck 38: E895–E904, 2016
Funding Information
  • Chung Shan Medical University Hospital (CSH-2013-A-030)
  • Ministry of Science and Technology in Taiwan (MOST-103-2314-B-040-015-MY3)

This publication has 51 references indexed in Scilit: